Format

Send to

Choose Destination
Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F899-F905. doi: 10.1152/ajprenal.00158.2017. Epub 2017 Apr 26.

Distinct roles of arginases 1 and 2 in diabetic nephropathy.

Author information

1
Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.
2
Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
3
Clinical Research Institute of Montreal, Départment de Médecine, Université de Montréal, Montréal, Canada; and.
4
Department of Comparative Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
5
Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; AwadA@uthscsa.edu.

Abstract

Diabetes is the leading cause of end-stage renal disease, resulting in a significant health care burden and loss of economic productivity by affected individuals. Because current therapies for progression of diabetic nephropathy (DN) are only moderately successful, identification of underlying mechanisms of disease is essential to develop more effective therapies. We showed previously that inhibition of arginase using S-(2-boronoethyl)-l-cysteine (BEC) or genetic deficiency of the arginase-2 isozyme was protective against key features of nephropathy in diabetic mouse models. However, those studies did not determine whether all markers of DN were dependent only on arginase-2 expression. The objective of this study was to identify features of DN that are associated specifically with expression of arginase-1 or -2. Elevated urinary albumin excretion rate and plasma urea levels, increases in renal fibronectin mRNA levels, and decreased renal medullary blood flow were associated almost completely and specifically with arginase-2 expression, indicating that arginase-2 selectively mediates major aspects of diabetic renal injury. However, increases in renal macrophage infiltration and renal TNF-α mRNA levels occurred independent of arginase-2 expression but were almost entirely abolished by treatment with BEC, indicating a distinct role for arginase-1. We therefore generated mice with a macrophage-specific deletion of arginase-1 (CD11bCre /Arg1fl/fl ). CD11bCre /Arg1fl/fl mice had significantly reduced macrophage infiltration but had no effect on albuminuria compared with Arg1fl/fl mice after 12 wk of streptozotocin-induced diabetes. These results indicate that selective inhibition of arginase-2 would be effective in preventing or ameliorating major features of diabetic renal injury.

KEYWORDS:

arginase; macrophages

PMID:
28446459
PMCID:
PMC5668588
DOI:
10.1152/ajprenal.00158.2017
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center